Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic Actual rates for 2021 lagged behind projections Sep 25, 2024
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms? News, features, and commentary about cancer-related issues Sep 19, 2024
Novel Agent Effective for Cancer Wasting Disorder Cancer patients with cachexia added needed pounds with GDF-15 antibody Sep 18, 2024
Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer News, features, and commentary about cancer-related issues Sep 12, 2024
Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan Sep 11, 2024
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC However, plinabulin plus docetaxel still "not ready for prime time," expert says Sep 10, 2024
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC Absolute improvement of almost 30%, doubling of duration of response with savolitinib Sep 10, 2024
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC Two-trial analysis shows about a 40% decreased risk of disease recurrence or death Sep 09, 2024
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC Novel agent nearly halved risk of progression as first-line therapy in phase III trial Sep 09, 2024
Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy Sep 09, 2024
Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza' News, features, and commentary about cancer-related issues Aug 30, 2024
Trial Questions Role of Dual Immunotherapy in First-Line NSCLC In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity Aug 22, 2024
Researchers Challenge USPSTF's Lung Cancer Screening Criteria Alternate criteria based on years of smoking has higher sensitivity and specificity, study says Aug 20, 2024
Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib Aug 20, 2024
Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests More data for discussion of controversial association between steroids, immunotherapy Aug 19, 2024
FDA Expands Durvalumab Label to Operable Lung Cancer PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery Aug 16, 2024
No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire News, features, and commentary about cancer-related issues Aug 09, 2024
Cancer Screening Costs Over $43 Billion a Year in the U.S., Study Estimates Colorectal cancer screening accounted for 64% of the total amount Aug 05, 2024
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies News, features, and commentary about cancer-related issues Aug 02, 2024
Ancient DNA May Fuel Cancer; ASCO Appeals to Oncologists; Pesticide Cancer Risk News, features, and commentary about cancer-related issues Jul 26, 2024
FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials Committee unanimously backs mandating trial design to distinguish effects of therapy phases Jul 25, 2024
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll News, features, and commentary about cancer-related issues Jul 12, 2024
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT News, features, and commentary about cancer-related issues Jul 05, 2024
Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer Discussion highlights insights from the LAURA trial and others on emerging treatments Jul 03, 2024 video
Vapers May Be Less Likely to Undergo Lung Cancer Screening "Former smokers who use e-cigarettes remain at increased risk of lung cancer," researchers say Jul 02, 2024
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials News, features, and commentary about cancer-related issues Jun 28, 2024
Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injury Case reports may not be as reliable, researchers say Jun 25, 2024
Court: Some Employers Can Exclude PrEP, Cancer Screenings From Insurance Coverage Not all preventive care recommended by the USPSTF is threatened by the narrow ruling, however Jun 24, 2024
EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer News, features, and commentary about cancer-related issues Jun 21, 2024
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response Jun 20, 2024
Early Menopause Tied to Higher Risk of Respiratory Mortality Greatest risk observed for women with bilateral oophorectomy Jun 13, 2024
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break? News, features, and commentary about cancer-related issues Jun 13, 2024
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer Half of patients responded, but editorialists call for new directions in therapy development Jun 11, 2024
Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma Immunotherapy may have been given too late, researchers suggested Jun 10, 2024
Lung Cancer Screening Rates Remain Low in the U.S., Especially in the South But one study showed that patient navigation added to usual care may increase uptake Jun 10, 2024
Artery Inflammation and CV Events; Stepped Palliative Care for Lung Cancer Patients Also in TTHealthWatch: diets and medicine in IBS and active surveillance in prostate cancer Jun 08, 2024 podcast
'Unusual' Cancers After Pandemic; A Win in TNBC; Shortage Pauses Clinical Trial News, features, and commentary about cancer-related issues Jun 06, 2024
Industry Clinic β’ Ad Insights What Will It Take to Deliver Both Health & Care in Oncology? Jun 04, 2024
Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumab Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group Jun 03, 2024
'Practice Changing' Trial for Inoperable Locally Advanced NSCLC EGFR testing now needed for all patients with stage III disease, experts say Jun 02, 2024
